Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $1,792,772.30 in Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 277,090 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the sale, the chief executive officer now directly owns 4,029,374 shares in the company, valued at $26,070,049.78. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Humacyte Stock Performance

HUMA traded down $0.30 on Thursday, reaching $6.15. The company had a trading volume of 1,974,594 shares, compared to its average volume of 2,174,274. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $9.97. The stock has a market cap of $732.37 million, a P/E ratio of -6.15 and a beta of 1.52. The company’s fifty day moving average is $6.84 and its 200 day moving average is $5.44. The company has a debt-to-equity ratio of 0.61, a quick ratio of 8.37 and a current ratio of 8.37.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in Humacyte in the 2nd quarter valued at about $28,000. Tower Research Capital LLC TRC grew its stake in Humacyte by 261.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after buying an additional 6,504 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Humacyte in the 4th quarter valued at about $29,000. Kovitz Investment Group Partners LLC acquired a new position in Humacyte in the 4th quarter valued at about $35,000. Finally, Principal Financial Group Inc. acquired a new position in shares of Humacyte during the 2nd quarter worth approximately $83,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on HUMA. Benchmark reissued a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Monday, August 12th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Humacyte in a research note on Tuesday, July 2nd. Finally, BTIG Research boosted their price objective on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.60.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.